BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
6 Asian Urban areas to Visit - 2Vote in favor of your Number one Kind of Shades
- 3The most effective method to Decide the Best Auto Crash Attorney for Your Lawful Necessities
- 4Lilly, Novo lock horns in India's obesity drug race
- 5What happened to Eleven after the ambiguous 'Stranger Things' series finale? Millie Bobby Brown knows — but 'swore herself to secrecy'
- Which Carrier Do You Suggest? Vote
- Watch India launch advanced military satellite on rocket's 1st flight since May 2025 failure
- 5 Eating routine Well disposed Snacks to Keep You Fulfilled
- Which Diet Prompts the Incomparable Wellbeing Results?
- Figure out How to Use Your Nursing Abilities for Better Compensation
- Forum Dvorah demands clear support for women in combat as IDF gender debate escalates
- How Much Has the Iran War Cost the Average American Per Day?
- US FDA declines to approve Corcept's drug for rare hormonal disorder
- Was This Driver Simply Having A great time Or Behaving Like An Ass?
